ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v11i3.1006ppharm-95Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESФАКТОРЫ РИСКА ФОРМИРОВАНИЯ БРОНХОЛЕГОЧНОЙ ДИСПЛАЗИИ У НОВОРОЖДЕННЫХ С ОЧЕНЬ НИЗКОЙ И ЭКСТРЕМАЛЬНО НИЗКОЙ МАССОЙ ТЕЛА ПРИ РОЖДЕНИИRISK FACTORS OF BRONCHOPULMONARY DYSPLASIA DEVELOPMENT IN NEONATES WITH VERY LOW AND EXTREMELY LOW BIRTH WEIGHTЛебедеваО. В.LebedevaO. V.

кандидат медицинских наук, докторант кафедры госпитальной педиатрии с курсом последипломногообразования ГБОУ ВПО «Астраханская государственная медицинская академия» Минздрава России

MD, doctoral student at the department of hospital pediatrics with a course of postgraduate education of the Astrakhan State Medical Academy of the Ministry of Health of Russia (State Budgetary Educational Institution of Higher Professional Education)

lebedevadoc@gmail.comАстраханская государственная медицинская академия Минздрава РоссииРоссияAstrakhan State Medical Academy of the Ministry of Health of RussiaRussian Federation201403062014113Педиатрическая фармакология3741Copyright © Лебедева О.В., 20142014Лебедева О.В.Lebedeva O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/95

The study was aimed at investigating the perinatal factors and levels of pro- (IL1α, IL6) and anti-inflammatory (IL1RA, IL10) cytokines in order to clarify their role in immune pathogenesis and prediction of bronchopulmonary dysplasia (BPD). Patients and methods: the prospective study involved 194 neonates with birth weight of 600-1,500 g and gestational age of 25‑32 weeks. The primary perinatal risk factors and their role in BPD development in children with very low (VLBW) and extremely low (ELBW) birth weight were analyzed. A special screening program consisted in determining serum levels of IL1α, IL1RA, IL6 and IL10 in the 3rd-5th and the 7th-10th day of life with enzyme-linked immunosorbent assay using test systems manufactured by Cytokine, LLC. 40 neonates with and 40 neonates without BPD underwent immunological examination. The BPD incidence was 46.6% in neonates with ELBW and 10.5% in children with VLBW. BPD risk factors for BPD in VLBW neonates were low APGAR score in the 1st minute (p = 0.02), severe respiratory distress syndrome (RDS; p < 0.001) and pneumonia (p < 0.001). Gestational age under 27 weeks (p = 0.001) had the primary role in children with ELBW; other risk factors included body weight (p = 0.02), low APGAR score in the 1st (p = 0.03) and the 5th minutes (p = 0.002), severe RDS (p < 0.001) and pneumonia development (p < 0.001). According to the comparative evaluation of prognostic significance of the level of pro-and anti-inflammatory cytokines in infants with BPD, IL1RA has the highest information value when its level > 670 pg/ml and IL6 ≥ 25 pg/ml.

 

бронхолегочная дисплазияфакторы рискацитокиныноворожденныеbronchopulmonary dysplasiarisk factorscytokinesneonatesReferencesMosca F., Colnaghi M., Fumagalli M. BPD: old and new problems. J Matern Fetal Neonatal Med. 2011; 24 (1): 80–82.Mosca F., Colnaghi M., Fumagalli M. BPD: old and new problems. J. Matern. Fetal. Neonatal Med. 2011; 24 (1): 80–82.Chess P. R., D'Angio C. T., Pryhuber G. S., Maniscalco W. M. Pathogenesis of bronchopulmonary dysplasia. Semin Perinatol. 2006; 30 (4): 171–178.Chess P. R., D'Angio C. T., Pryhuber G. S., Maniscalco W. M. Pathogenesis of bronchopulmonary dysplasia. Semin. Perinatol. 2006; 30 (4): 171–178.Современные подходы к профилактике, диагностике и лечению бронхолегочной дисплазии. Руководство для практикующих врачей. Под ред. А. А. Баранова, Л. С. Намазовой-Барановой, И. В. Давыдовой. М.: Издательство «ПедиатрЪ». 2013.Sovremennye podkhody k profilaktike, diagnostike i lecheniyu bronkholegochnoi displazii. Rukovodstvo dlya praktikuyushchikh vrachei. Pod red. A. A. Baranova, L. S. Namazovoi-Baranovoi, I. V. Davydovoi [Current Approaches to Prevention, Diagnosis and Treatment of Bronchopulmonary Dysplasia. Guidelines for clinicians. Ed. A.A. Baranov, L.S. Namazova-Baranova, I.V. Davydova]. Moscow, Publishing house «Pediatr""», 2013.Овсянников Д. Ю. Бронхолегочная дисплазия: естественное развитие, исходы и контроль. Педиатрия. 2011; 90 (1): 143–150.Ovsyannikov D. Yu. Pediatriya = Pediatrics. 2011; 90 (1): 143–150.Ozkan H., Cetinkaya M., Koksal N. Increased incidence of bronchopulmonary dysplasia in preterm infants exposed to preeclampsia. J Matern Fetal Neonatal Med. 2012; 25 (12): 2681–2685.Ozkan H., Cetinkaya M., Koksal N. Increased incidence of bronchopulmonary dysplasia in preterm infants exposed to preeclampsia. J. Matern. Fetal. Neonatal. Med. 2012; 25 (12): 2681–2685.Hartling L., Liang Y., Lacaze-Masmonteil T. Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal. 2012; 97 (1): 8–17.Hartling L., Liang Y., Lacaze-Masmonteil T. Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch. Dis. Child Fetal. Neonatal. 2012; 97 (1): 8–17.Hofer N., Kothari R., Morris N., Muller W., Resch B. The fetal inflammatory response syndrome is a risk factor for morbidity in preterm neonates. Am J Obstet Gynecol. 2013; 209 (6): 542.Hofer N., Kothari R., Morris N., Muller W., Resch B. The fetal inflammatory response syndrome is a risk factor for morbidity in preterm neonates. Am. J. Obstet Gynecol. 2013; 209 (6): 542.Usuda T., Kobayashi T., Sakakibara S., Kobayashi A., Kaneko T., Wada M., Onozuka J., Numata O., Torigoe K., Yamazaki H., Sato T., Nagayama Y., Uchiyama M. Interleukin-6 polymorphism and bronchopulmonary dysplasia risk in very low-birthweight infants. Pediatr Int. 2012; 54 (4): 471–475.Usuda T., Kobayashi T., Sakakibara S., Kobayashi A., Kaneko T., Wada M., Onozuka J., Numata O., Torigoe K., Yamazaki H., Sato T., Nagayama Y., Uchiyama M. Interleukin-6 polymorphism and bronchopulmonary dysplasia risk in very low-birthweight infants. Pediatr. Int. 2012; 54 (4): 471–475.Bhandari A., Bhandari V. Biomarkers in bronchopulmonary dysplasia. Paediatr. Respir Rev. 2013; 14 (3): 173–179.Bhandari A., Bhandari V. Biomarkers in bronchopulmonary dysplasia. Paediatr. Respir. Rev. 2013; 14 (3): 173–179.Ambalavanan N., Carlo W. A., D'Angio C. T., McDonald S. A., Das A., Schendel D., Thorsen P., Higgins R. D. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics. 2009; 123 (4): 1132–1141.Ambalavanan N., Carlo W. A., D'Angio C. T., McDonald S. A., Das A., Schendel D., Thorsen P., Higgins R. D. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics. 2009; 123 (4): 1132–1141.Koksal N., Kayik B., Cetinkaya M., Ozkan H., Budak F., Kilic S., Canitez Y., Oral B. Value of serum and bronchoalveolar fluid lavage pro- and anti-inflammatory cytokine levels for predicting bronchopulmonary dysplasia in premature infants. Eur Cytokine Netw. 2012; 23 (2): 29–35.Koksal N., Kayik B., Cetinkaya M., Ozkan H., Budak F., Kilic S., Canitez Y., Oral B. Value of serum and bronchoalveolar fluid lavage pro- and anti-inflammatory cytokine levels for predicting bronchopulmonary dysplasia in premature infants. Eur. Cytokine Netw. 2012; 23 (2): 29–35.Kakkera D. K., Siddiq M. M., Parton L. A. Interleukin-1 balance in the lungs of preterm infants who develop bronchopulmonary dysplasia. Biol Neonate. 2005; 87 (2): 82–90.Kakkera D. K., Siddiq M. M., Parton L. A. Interleukin-1 balance in the lungs of preterm infants who develop bronchopulmonary dysplasia. Biol. Neonate. 2005; 87 (2): 82–90.Hikino S., Ohga S., Kinjo T., Kusuda T., Ochiai M., Inoue H., Honjo S., Ihara K., Ohshima K., Hara T. Tracheal aspirate gene expression in preterm newborns and development of broncho pul-monary dysplasia. Pediatr Int. 2012; 54 (2): 208–214.Hikino S., Ohga S., Kinjo T., Kusuda T., Ochiai M., Inoue H., Honjo S., Ihara K., Ohshima K., Hara T. Tracheal aspirate gene expression in preterm newborns and development of broncho pulmonary dysplasia. Pediatr. Int. 2012; 54 (2): 208–214.Классификация клинических форм бронхолегочных заболеваний у детей. М.: Российское респираторное общество. 2009. С. 18.Klassifikatsiya klinicheskikh form bronkholegochnykh zabolevanii u detei [Classification of the Clinical Forms of Bronchopulmonary Diseases in Children]. Moscow, Russian respiratory society, 2009. p. 18.Лебедева О. В. Прогностическое значение цитокинов для оценки риска развития пневмоний у глубоконедоношенных новорожденных с респираторным дистресс-синдромом. Вопросы диагностики в педиатрии. 2012; 4 (1): 24–27.Lebedeva O. V. Voprosy diagnostiki v pediatrii = Diagnostics in pediatrics. 2012; 4 (1): 24–27.Davidson D., Miskolci V., Clark D. C., Dolmaian G., Vancurova I. Interleukin-10 production after pro-inflammatory stimulation of neutrophils and monocytic cells of the newborn. Comparison to exogenous interleukin-10 and dexamethasone levels needed to inhibit chemokine release. Neonatology. 2007; 92 (2): 127–133.Davidson D., Miskolci V., Clark D. C., Dolmaian G., Vancurova I. Interleukin-10 production after pro-inflammatory stimulation of neutrophils and monocytic cells of the newborn. Comparison to exogenous interleukin-10 and dexamethasone levels needed to inhibit chemokine release. Neonatology. 2007; 92 (2): 127–133.

The authors declare that there are no conflicts of interest present.